IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lessened by Tower Bridge Advisors

Tower Bridge Advisors lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,509 shares of the medical research company’s stock after selling 1,190 shares during the quarter. IQVIA makes up approximately 1.9% of Tower Bridge Advisors’ holdings, making the stock its 10th largest holding. Tower Bridge Advisors’ holdings in IQVIA were worth $17,893,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Maxwell Wealth Strategies Inc. lifted its stake in shares of IQVIA by 37.3% during the 3rd quarter. Maxwell Wealth Strategies Inc. now owns 11,570 shares of the medical research company’s stock worth $2,742,000 after purchasing an additional 3,145 shares during the period. Natixis Advisors LLC increased its stake in IQVIA by 26.9% in the third quarter. Natixis Advisors LLC now owns 245,136 shares of the medical research company’s stock valued at $58,090,000 after purchasing an additional 51,970 shares during the last quarter. Mizuho Securities USA LLC lifted its position in IQVIA by 1,397.9% during the third quarter. Mizuho Securities USA LLC now owns 210,428 shares of the medical research company’s stock worth $49,865,000 after buying an additional 196,380 shares during the period. Simplify Asset Management Inc. boosted its stake in IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the last quarter. Finally, Empowered Funds LLC grew its holdings in IQVIA by 33.9% in the 3rd quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company’s stock valued at $814,000 after buying an additional 871 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Truist Financial decreased their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. JPMorgan Chase & Co. reduced their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Finally, BTIG Research dropped their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $259.13.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is currently owned by insiders.

IQVIA Trading Down 5.1 %

IQV opened at $192.68 on Friday. The firm’s 50 day moving average is $226.95 and its 200-day moving average is $228.27. IQVIA Holdings Inc. has a 52-week low of $189.63 and a 52-week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $34.97 billion, a P/E ratio of 25.29, a P/E/G ratio of 1.98 and a beta of 1.51.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.